Lunit Cancer Screening

Lunit Cancer Screening is a healthcare technology company based in Seoul, South Korea, with a significant presence in Boston, Massachusetts. Founded in 2013, Lunit specializes in artificial intelligence (AI) solutions for cancer diagnostics and treatment. The company develops advanced AI software to assist medical professionals in cancer screening and personalized treatment, aiming to improve cancer outcomes through precise diagnosis and treatment decisions. Lunit's key offerings include the Lunit INSIGHT Suite, which features AI tools for breast cancer detection, such as Lunit INSIGHT MMG for mammography analysis and Lunit INSIGHT DBT for digital breast tomosynthesis. These tools enhance the efficiency of radiologists by reducing their workload while maintaining high screening quality. Additionally, Lunit SCOPE provides AI solutions for optimizing cancer treatment through biomarker analysis. The company also introduced a comprehensive ecosystem for cancer detection and care in 2024, integrating various AI technologies to support the entire cancer care continuum. With its AI solutions deployed in over 4,800 medical institutions across more than 55 countries, Lunit has established a strong global presence. The company collaborates with major medical device companies to integrate its technology into existing healthcare systems, further expanding its impact on cancer care.